79 unchanged sentences
001-37581), filed with the SEC on August 1, 2017).
−Removed: Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc.
−Removed: Inducement Plan (incorporated herein by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No.
−Removed: 001-37581), filed with the SEC on August 1, 2017).
+Added: Sixth Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.12 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 24, 2022).
+Added: Seventh Amended and Restated Non-Employee Director Compensation Policy (incorporated herein by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 24, 2022).
+Added: Eighth Amended and Restated Non-Employee Director Compensation Policy.
Form of Indemnification Agreement (incorporated by reference to Exhibit 10.12 to the Registrant’s Registration Statement on Form S-1 (File No.
333-206437), filed with the SEC on August 17, 2015).
−Removed: Sixth Amended and Restated Non-Employee Director Compensation Policy.
+Added: Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson (incorporated herein by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 24, 2022).
Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Neal Walker (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
001-37581), filed with the SEC on January 14, 2022).
+Added: Letter Agreement, dated as of November 22, 2022, by and between the Registrant and Neal Walker.
Amended and Restated Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Frank Ruffo (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
001-37581), filed with the SEC on January 14, 2022).
−Removed: Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Joseph Monahan.
−Removed: Employment Agreement, dated as of January 31, 2022, by and between the Registrant and James Loerop.
−Removed: Severance Agreement and General Release, dated as of November 1, 2021, by and between the Registrant and Kamil Ali-Jackson.
−Removed: Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon.
+Added: Separation Agreement and General Release, dated as of December 9, 2022, by and between the Registrant and Frank Ruffo.
+Added: Consulting Agreement, dated as of January 1, 2023, by and between the Registrant and Frank Ruffo.
+Added: Employment Agreement, dated as of January 12, 2022, by and between the Registrant and Joseph Monahan (incorporated herein by reference to Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 24, 2022).
+Added: Employment Agreement, dated as of January 31, 2022, by and between the Registrant and James Loerop (incorporated herein by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 24, 2022).
+Added: Employment Agreement, dated as of August 1, 2022, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
+Added: 001-37581), filed with the SEC on August 1, 2022).
+Added: Amended and Restated Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Douglas Manion.
+Added: Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Kevin Balthaser.
+Added: Employment Agreement, dated as of June 27, 2022, by and between the Registrant and Gail Cawkwell (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No.
+Added: 001-37581), filed with the SEC on August 3, 2022).
+Added: Severance Agreement and General Release, dated as of January 7, 2022, by and between the Registrant and David Gordon (incorporated herein by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 24, 2022).
Sublease, dated November 2, 2017, by and between the Registrant and Auxilium Pharmaceuticals, LLC (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No.
7 unchanged sentences
001-37581), filed with the SEC on May 20, 2021) .
−Removed: Seventh Amended and Restated Non-Employee Director Compensation Policy.
Subsidiaries of the Registrant.
25 unchanged sentences
ACLARIS THERAPEUTICS, INC.
−Removed: /s/ Neal Walker
+Added: /s/ Douglas Manion
+Added: Douglas Manion
President and Chief Executive Officer
February 23, 2023
−Removed: KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Neal Walker and Frank Ruffo, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Aclaris Therapeutics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
+Added: KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Douglas Manion and Kevin Balthaser, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Aclaris Therapeutics, Inc., and any or all amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
−Removed: /s/ Neal Walker
+Added: /s/ Douglas Manion
President, Chief Executive Officer and Director
February 23, 2023
+Added: Douglas Manion
(Principal Executive Officer)
−Removed: /s/ Frank Ruffo
+Added: /s/ Kevin Balthaser
Chief Financial Officer
February 23, 2023
+Added: Kevin Balthaser
(Principal Financial Officer and Principal Accounting Officer)
−Removed: /s/ Christopher Molineaux
+Added: /s/ Neal Walker
Chairman of the Board of Directors
February 23, 2023
+Added: /s/ Christopher Molineaux
+Added: Lead Independent Director
+Added: February 23, 2023
Christopher Molineaux
20 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.